125 related articles for article (PubMed ID: 37713096)
1. Pharmacokinetics of Henagliflozin in Dialysis Patients with Diabetes.
Ding L; Liu S; Yan H; Li Z; Zhou Y; Pang H; Lu R; Zhang W; Che M; Wang L; Wang Q; Fang W; Zhang M; Che X; Gu L
Clin Pharmacokinet; 2023 Nov; 62(11):1581-1587. PubMed ID: 37713096
[TBL] [Abstract][Full Text] [Related]
2. Effects of Food on the Pharmacokinetic Properties and Mass Balance of Henagliflozin in Healthy Male Volunteers.
Chen ZD; Chen Q; Zhu YT; Zhang YF; Zhan Y; Chen XF; Liang X; Jia JY; Yu C; Liu HY; Zou JJ; Liu YM; Zhong DF
Clin Ther; 2021 Sep; 43(9):e264-e273. PubMed ID: 34366153
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Pharmacodynamics of Henagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Chinese Patients with Type 2 Diabetes Mellitus.
Yong X; Wen A; Liu X; Liu H; Liu YP; Li N; Hu T; Chen Y; Wang M; Wang L; Dai X; Huang J; Li J; Shen H
Clin Drug Investig; 2016 Mar; 36(3):195-202. PubMed ID: 26692004
[TBL] [Abstract][Full Text] [Related]
4. No apparent pharmacokinetic interactions were found between henagliflozin: A novel sodium-glucose co-transporter 2 inhibitor and glimepiride in healthy Chinese male subjects.
Que L; Huang K; Xiang X; Ding Y; Chu N; He Q
J Clin Pharm Ther; 2022 Aug; 47(8):1225-1231. PubMed ID: 35362180
[TBL] [Abstract][Full Text] [Related]
5. Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Henagliflozin, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter 2, in Healthy Subjects Following Single- and Multiple-dose Administration.
Zhang YF; Liu YM; Yu C; Wang YT; Zhan Y; Liu HY; Zou JJ; Jia JY; Chen Q; Zhong DF
Clin Ther; 2021 Feb; 43(2):396-409. PubMed ID: 33454124
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and Pharmacodynamic Interactions Between Henagliflozin, a Novel Selective SGLT-2 Inhibitor, and Warfarin in Healthy Chinese Subjects.
He X; Liu G; Chen X; Wang Y; Liu R; Wang C; Huang Y; Shen J; Jia Y
Clin Ther; 2023 Jul; 45(7):655-661. PubMed ID: 37451912
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of drug-drug interaction between henagliflozin, a novel sodium-glucose co-transporter 2 inhibitor, and metformin in healthy Chinese males.
Wang L; Wu C; Shen L; Liu H; Chen Y; Liu F; Wang Y; Yang J
Xenobiotica; 2016 Aug; 46(8):703-8. PubMed ID: 26608671
[TBL] [Abstract][Full Text] [Related]
8. Effects of Food and Multiple-dose Administration on the Pharmacokinetic Properties of HR20033, a Sustained-release Formulation of Henagliflozin and Metformin for the Treatment of Diabetes, in Healthy Chinese Volunteers.
Liu Y; Huyan X; Zhang Q; Qing H; Zhang Q; Wang X; Li Y; Liu Z; Hu W
Clin Pharmacol Drug Dev; 2023 Apr; 12(4):376-384. PubMed ID: 36408821
[TBL] [Abstract][Full Text] [Related]
9. Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Weng J; Zeng L; Zhang Y; Qu S; Wang X; Li P; Fu L; Ma B; Ye S; Sun J; Lu W; Liu Z; Chen D; Cheng Z; Liu H; Zhang T; Zou J
Diabetes Obes Metab; 2021 Aug; 23(8):1754-1764. PubMed ID: 33769656
[TBL] [Abstract][Full Text] [Related]
10. Henagliflozin monotherapy in patients with type 2 diabetes inadequately controlled on diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial.
Lu J; Fu L; Li Y; Geng J; Qin L; Li P; Zheng H; Sun Z; Li Y; Zhang L; Sun Y; Chen D; Qin G; Lu W; Guo Y; Zhang Y; Liu H; Zhang T; Zou J
Diabetes Obes Metab; 2021 May; 23(5):1111-1120. PubMed ID: 33417292
[TBL] [Abstract][Full Text] [Related]
11. Characterization and quantitative determination of henagliflozin metabolites in humans.
Chen Z; Li L; Zhan Y; Zhang Y; Liu H; Zou J; Zhong D
J Pharm Biomed Anal; 2021 Jan; 192():113632. PubMed ID: 33069964
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
Aweeka F; Jayesekara D; Horton M; Swan S; Lambrecht L; Wilner KD; Sherwood J; Anziano RJ; Smolarek TA; Turncliff RZ
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):27S-33S. PubMed ID: 10771451
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.
Sun L; Ding L; Wang Y; Zhou W; Yan Z; Sun W; Zhang H; Ou N; Chen X
Drugs R D; 2012 Mar; 12(1):17-28. PubMed ID: 22339483
[TBL] [Abstract][Full Text] [Related]
14. Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study.
Tan QY; Li HD; Zhu RH; Zhang QZ; Zhang J; Peng WX
Am J Cardiovasc Drugs; 2013 Feb; 13(1):17-25. PubMed ID: 23355361
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of the Melanocortin Type 1 Receptor Agonist PL8177 After Subcutaneous Administration.
Dodd J; Jordan R; Makhlina M; Pesco Koplowitz L; Koplowitz B; Barnett K; Yang WH; Spana C
Drugs R D; 2021 Dec; 21(4):431-443. PubMed ID: 34693509
[TBL] [Abstract][Full Text] [Related]
16. Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function.
Pescovitz MD; Pruett TL; Gonwa T; Brook B; McGory R; Wicker K; Griffy K; Robinson CA; Jung D
Transplantation; 1998 Oct; 66(8):1104-7. PubMed ID: 9808499
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, Safety and Tolerability of Chiglitazar, A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Pan-Agonist, in Healthy Chinese Volunteers: A Phase I Study.
Xu HR; Zhang JW; Chen WL; Ning ZQ; Li XN
Clin Drug Investig; 2019 Jun; 39(6):553-563. PubMed ID: 31037611
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the pharmacokinetics, removal rate of hemodialysis, and safety of lactulose in hemodialysis patients.
Lin CJ; Pan CF; Ju SY; Tzeng HK; Chen SW; Syu JT; Wu CJ
J Food Drug Anal; 2016 Oct; 24(4):876-880. PubMed ID: 28911627
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic Properties of Dapagliflozin in Hemodialysis and Peritoneal Dialysis Patients.
Barreto J; Borges C; Rodrigues TB; Jesus DC; Campos-Staffico AM; Nadruz W; Luiz da Costa J; Bueno de Oliveira R; Sposito AC
Clin J Am Soc Nephrol; 2023 Aug; 18(8):1051-1058. PubMed ID: 37227937
[TBL] [Abstract][Full Text] [Related]
20. Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers.
Schulz HU; Schürer M; Bässler D; Weiser D
Arzneimittelforschung; 2005; 55(10):561-8. PubMed ID: 16294501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
